When the expressing construct was transfected into the two cancer cells, MIR31HG level was augmented by ~ 4-fold for SW579 cells and ~ 5-fold for TPC-1 cells (Fig. 3G), validating the MIR31HG upregulation efficacy of the construct. The gene discussed is MIR31HG; the disease is cancer.